Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 19/20 | 0.51 |
| ▸ | ITGB2 | P05107 | 18/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 18/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847515 | 0.87 | ITGAL (0.55) | ITGALITGB2ICAM1 | |
| SCHEMBL5657327 | 0.87 | ITGAL (0.55) | ITGALITGB2ICAM1 | |
| SCHEMBL4841707 | 0.78 | ITGAL (0.55) | ITGALITGB2ICAM1 | |
| SCHEMBL4847241 | 0.77 | ITGAL (0.54) | ITGALITGB2ICAM1 | |
| SCHEMBL4840686 | 0.77 | ITGAL (0.54) | ITGALITGB2ICAM1 | |
| SCHEMBL4847526 | 0.77 | ITGAL (0.47) | ITGALITGB2ICAM1 | |
| SCHEMBL4847530 | 0.77 | ITGAL (0.47) | ITGALITGB2ICAM1 | |
| SCHEMBL14254718 | 0.76 | ITGAL (0.48) | ITGALITGB2ICAM1 | |
| SCHEMBL4849098 | 0.76 | ITGAL (0.48) | ITGALITGB2ICAM1 | |
| SCHEMBL4849044 | 0.76 | ITGAL (0.53) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339718-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | claimed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | claimed |
| US-6710064-B2 | FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES | BRISTOL-MYERS SQUIBB CO. | 2004-03-23 | — | — | US | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | ITGAL 3218/4885ITGB2 4732/4885ICAM1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.